Advances in Asthma, Allergy and Immunology Series 2004: Basic and clinical immunology

Journal of Allergy and Clinical Immunology

Volumn 114, Issue 2, 2004, Pages 398-405

  Chinen, Javier ^a   Shearer, William T ^b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b Building 49 ^*

Author keywords

ADA; Adenosine deaminase; Combined variable immunodeficiency; CVID; DC; Dendritic cell; gene therapy; hBD; HIV; Human defensin; ICOS; immunodeficiency; Immunology; Inducible costimulator of activated T cells; IVIG; lymphocyte subsets; regulatory T cells

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCG VACCINE; CD150 ANTIGEN; CD4 ANTIGEN; DEFENSIN; FAS ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN M; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; OLIGOPEPTIDE; PHOSPHOLIPASE A2; T BOX TRANSCRIPTION FACTOR; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ALLERGY; ANTIGEN PRESENTATION; APOPTOSIS; ASTHMA; BRONCHITIS; CELL PROLIFERATION; CLINICAL IMMUNOLOGY; DENDRITIC CELL; DRUG MECHANISM; EOSINOPHIL; GENE THERAPY; GENETIC DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOTHERAPY; LANGERHANS CELL; LOW DRUG DOSE; LUNG LAVAGE; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; NEUTROPHIL; NONHUMAN; OCCUPATIONAL ASTHMA; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TH1 CELL; TH2 CELL; THROMBOEMBOLISM;

EID: 4344586383     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2004.05.036     Document Type: Article

References (54)

1. Herrick C.A., Das J., Xu L., Wisnewski A.V., Redlich C.A., Bottomly K. Differential roles for CD4 and CD8 T cells after diisocyanate sensitization: genetic control of TH2-induced lung inflammation. J Allergy Clin Immunol. 111:2003;1087-1094
2. Cates E.C., Gajewska B.U., Goncharova S., Alvarez D., Fattouh R., Coyle A.J., et al. Effect of GM-CSF on immune, inflammatory, and clinical responses to ragweed in a novel mouse model of mucosal sensitization. J Allergy Clin Immunol. 111:2003;1076-1086
3. Kusunoki T., Sugai M., Katakai T., Omatsu Y., Iyoda T., Inaba K., et al. TH2 dominance and defective development of a CD8+ dendritic cell subset in Id2-deficient mice. J Allergy Clin Immunol. 111:2003;136-142
4. Yokota Y., Mansouri A., Mori S., Sugawara S., Adachi S., Nishikawa S.I., et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature. 397:1999;702-706
5. Habib T., Nelson A., Kaushansky K. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol. 112:2003;1033-1045
6. McHugh R.S., Shevach H.M. The role of suppressor T cells in the regulation of immune responses. J Allergy Clin Immunol. 110:2002;693-702
7. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:2003;1057-1061
8. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immun. 4:2003;330-336
9. Khattri R., Cox T., Yasayko S.-A., Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immun. 4:2003;337-342
10. Chatila T.A., Blaeser F., Ho N., Lederman H.M., Voulgaropoulos C., Helms C., et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation (sic) syndrome. J Clin Invest. 106:2000;R75-R81
11. Umetsu D.T., Akbari O., Dekruyff R.H. Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol. 112:2003;480-487
12. Bellinghausen I., Klostermann B., Knop J., Saloga J. Human CD4+CD25+ T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production. J Allergy Clin Immunol. 111:2003;862-868
13. Allam J.P., Novak N., Fuchs C., Asen S., Berge S., Appel T., et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FceRI expression. J Allergy Clin Immunol. 112:2003;141-148
14. Foster B., Metcalfe D.D., Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FcepsilonRI: correlation with serum IgE and allergic asthma. J Allergy Clin Immunol. 112:2003;1132-1138
15. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol. 20:2002;197-216
16. Yamamoto M., Takeda K., Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol. 40:2004;861-868
17. Hoebe K., Du X., Georgel P., Janssen E., Tabeta K., Kim S.O., et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signaling. Nature. 424:2003;743-748
18. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 301:2003;640-643
19. Shearer W.T., Rosenblatt H.M., Gelman R.S., Oyomopito R., Plaeger S., Stiehm E.R., et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 112:2003;973-980
20. Chinen J., Rosenblatt H.M., Smith E.O., Shearer W.T., Noroski L.M. Long-term assessment of T-cell populations in DiGeorge syndrome. J Allergy Clin Immunol. 111:2003;573-579
21. Winkelstein J.A., Marino M.C., Ochs H., Fuleihan R., Scholl P.R., Geha R., et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 82:2003;373-384
22. Grimbacher B., Hutloff A., Schlesier M., Glocker E., Warnatz K., Drager R., et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol. 4:2003;261-268
23. Dadi H.K., Simon A.J., Roifman C.M. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N Engl J Med. 349:2003;1821-1828
24. Imai K., Slupphaug G., Lee W.I., Revy P., Nonoyama S., Catalan N., et al. Human uracyl-DNA glycosylase deficiency is associated with profoundly impaired immunoglobulin class switch recombination. Nat Immunol. 4:2003;1023-1028
25. Hernandez P.A., Gorlin R.J., Lukens J.N., Taniuchi S., Bohinjec J., Francois R., et al. Mutations in the chemokine receptor CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet. 34:2003;70-73
26. Fieschi C., Dupuis S., Catherinot E., Feinberg J., Bustamante J., Breiman A., et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med. 197:2003;527-535
27. Dupuis S., Jouanguy E., Al-Hajjar S., Fieschi C., Al-Mohsen I.Z., Al-Jumaah S., et al. Impaired response to interferon-a/b and lethal viral disease in human STAT1 deficiency. Nat Genet. 33:2003;388-391
28. Picard C., Puel A., Bonnet M., Ku C.L., Bustamante J., Yang K., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 299:2003;2076-2079
29. Altznauer F., von Gunten S., Spath P., Simon H.U. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol. 112:2003;1185-1190
30. Brown H.C., Ballas Z.K. Acute thromboembolic events associated with intravenous immunoglobulin infusion in antibody-deficient patients. J Allergy Clin Immunol. 112:2003;797-799
31. Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C., De Villartay J.P., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 346:2002;1185-1193
32. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., LeDeist F., Wulfraat N., McIntyre E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 348:2003;255-256
33. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulfraat N., Leboulch P., et al. LMO-2 associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302:2003;415-419
34. Aiuti A., Brodignon C. Gene therapy for ADA deficiency. Science. 296:2002;2410-2413
35. Brightling C.E., Symon F.A., Birring S.S., Bradding P., Pavord I.D., Wardlaw A.J. TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol. 110:2002;899-905
36. Marks G.B., Ng K., Zhou J., Toelle B.G., Xuan W., Belousova E.G., et al. The effect of neonatal BCG vaccination on atopy and asthma at age 7 to 14 years: an historical cohort study in a community with a very low prevalence of tuberculosis infection and a high prevalence of atopic disease. J Allergy Clin Immunol. 111:2003;541-549
37. Laaksonen K., Junikka M., Lahesmaa R., Terho E.O., Savolainen J. In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. J Allergy Clin Immunol. 112:2003;1171-1177
38. Fellrath J.M., Kettner A., Dufour N., Frigerio C., Schneeberger D., Leimgruber A., et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol. 111:2003;854-861
39. Fiset P.O., Soussi-Gounni A., Christodoupoulos P., Tulic M., Sobol S.E., Frenkiel S., et al. Modulation of allergic response in nasal mucosa by antisense oligodeoxynucleotides for IL-4. J Allergy Clin Immunol. 111:2003;580-586
40. Shirai T., Magara K.K., Motohashi S., Yamashita M., Kimura M., Suwazono Y., et al. TH1-biased immunity induced by exposure to Antarctic winter. J Clin Immunol. 111:2003;1353-1360
41. Quinones-Mateu M.E., Lederman M.M., Feng Z., Chakraborty B., Weber J., Rangel H.R., et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS. 17:2003;F39-F49
42. Wang W., Cole A.M., Hong T., Waring A.J., Lehrer R.I. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J Immunol. 170:2003;4708-4716
43. Bailes E., Gao F., Bibollet-Ruche F., Courgnaud V., Peeters M., Marx P.A., et al. Hybrid origin of SIV in chimpanzees. Science. 300:2003;1713
44. Casartelli N., Di Matteo G., Argentini C., Cancrini C., Bernardi S., Castelli G., et al. Structural defects and variations in the HIV-1 nef gene from rapid, slow and non-progressor children. AIDS. 17:2003;1291-1301
45. Hess C., Altfeld M., Thomas S.Y., Addo M.M., Rosenberg E.S., Allen T.M., et al. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet. 363:2004;863-866
46. Feeney M.E., Draenert R., Roosevelt K.A., Pelton S.I., McIntosh K., Burchett S.K., et al. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. J Immunol. 171:2003;6968-6975
47. Scott Z.A., Beaumier C.M., Sharkey M., Stevenson M., Luzuriaga K. HIV-1 replication increases HIV-specific CD4+ T cell frequencies but limits proliferative capacity in chronically infected children. J Immunol. 170:2003;5786-5792
48. Poirier M.C., Divi R.L., Al-Harthi L., Olivero O.A., Nguyen V., Walker B., et al. Women and Infants Transmission Study (WITS) Group. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr. 33:2003;175-183
49. Siliciano J.D., Kajdas J., Finzi D., Quinn T.C., Chadwick K., Margolick J.B., et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 9:2003;727-728
50. Kilby J.M., Eron J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med. 348:2003;2228-2238
51. Lazzarin A., Clotet B., Cooper D., Reynes J., Arasteh K., Nelson M., et al. TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 348:2003;2186-2195
52. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., et al. TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 348:2003;2175-2185
53. Kawai K., Tsuno N.H., Kitayama J., Okaji Y., Yazawa K., Asakage M., et al. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J Allergy Clin Immunol. 112:2003;951-957
54. Nance C.L., Shearer W.T. Is green tea good for HIV-1 infection? J Allergy Clin Immunol. 112:2003;851-853